Floatz logo

Donanemab

Synucleinopathies

Eli Lilly and Companymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Synucleinopathies cohort.

Asset / SponsorPhaseRating
Tvp-1012
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3B
RDX-013 COMPONENT TENAPANOR
Cedar Valley Digestive Health Center
Phase 2CCC
PBR-06
Brigham and Women's Hospital
D
[18F]MNI-1216
Invicro
Early Phase 1NR

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →